You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

orelabrutinib

Showing 1 - 19 of 19
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Healthy Subject Trial in Beijing (Orelabrutinib and (orelabrutinib tablet simulator), Orelabrutinib, Placebo (orelabrutinib

Active, not recruiting
  • Healthy Subject
  • Orelabrutinib and placebo (orelabrutinib tablet simulator)
  • +3 more
  • Beijing, China
    Beijing GoBroad Boren Hospital
Dec 19, 2022

Follicular Lymphoma, Relapsed and Refractory Follicular Lymphoma Trial in Guangzhou (Orelabrutinib and Rituximab, Orelabrutinib)

Recruiting
  • Follicular Lymphoma
  • Relapsed and Refractory Follicular Lymphoma
  • Orelabrutinib and Rituximab
  • Orelabrutinib
  • Guangzhou, Guangdong, China
  • +2 more
Mar 23, 2022

CLL/SLL Trial in Beijing (orelabrutinib)

Recruiting
  • CLL/SLL
  • orelabrutinib
  • Beijing, Beijing, China
  • +1 more
Aug 5, 2022

DLBCL Trial in Suzhou (Orelabrutinib, Rituximab, CHOP-like Regimen)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Orelabrutinib
  • +2 more
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Aug 10, 2022

Primary CNS Lymphoma Trial in Shanghai (Orelabrutinib, Rituximab, Methotrexate (MTX))

Recruiting
  • Primary Central Nervous System Lymphoma
  • Orelabrutinib
  • +3 more
  • Shanghai, Shanghai, China
    Department of Hematology, Huashan Hospital, Fudan University
Jul 26, 2022

Primary CNS Lymphoma Trial in Hanzhou (Orelabrutinib, Rituximab, Methotrexate)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Orelabrutinib
  • +2 more
  • Hanzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 3, 2022

r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase

Not yet recruiting
  • B-cell Lymphoma
  • Orelabrutinib
  • Beijing, Beijing, China
    Deparment of Hematology, Peking University People's Hospital
Aug 9, 2022

Primary CNS Lymphoma Trial in Shanghai (Orelabrutinib)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Orelabrutinib
  • Shanghai, Shanghai, China
    Ruijin Hospital
Apr 18, 2022

Immune Thrombocytopenia Trial in Beijing (Orelabrutinib)

Not yet recruiting
  • Immune Thrombocytopenia
  • Orelabrutinib
  • Beijing, Beijing, China
    Peking University Institute of Hematology
Nov 6, 2021

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Nanjin (Orelabrutinib, Obinutuzumab, Fludarabine)

Recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Orelabrutinib
  • +3 more
  • Nanjin, Jiangsu, China
    Department of Haematology, the First Affiliated Hospital of Nanj
Apr 12, 2022

Primary CNS Lymphoma Trial in Beijing (Orelabrutinib, Pomalidomide, Rituximab)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Orelabrutinib
  • +3 more
  • Beijing, Beijing, China
  • +2 more
May 19, 2022

Neuromyelitis Optica Spectrum Disorder Trial in Beijing (Orelabrutinib)

Not yet recruiting
  • Neuromyelitis Optica Spectrum Disorder
  • Orelabrutinib
  • Beijing, Beijing, China
    Peking Union Medical College Hospital, Chinese Academy of Medica
Mar 16, 2022

Refractory and Relapsed Primary CNS Lymphoma, PCNSL, Non Hodgkin Lymphoma Trial in Guangzhou (Orelabrutinib, Thiotepa)

Not yet recruiting
  • Refractory and Relapsed Primary CNS Lymphoma
  • +2 more
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
Aug 19, 2021

Immune Thrombocytopenia, Bruton's Tyrosine Kinase Trial (Orelabrutinib)

Not yet recruiting
  • Immune Thrombocytopenia
  • Bruton's Tyrosine Kinase
  • Orelabrutinib
  • (no location specified)
Aug 18, 2021

Primary CNS Hodgkin Lymphoma Trial in Hangzhou (Orelabrutinib, Sintilimab)

Recruiting
  • Primary Central Nervous System Hodgkin Lymphoma
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jul 14, 2021

Primary CNS Lymphoma Trial in Beijing (orelabrutinib, Sintilimab, Tislelizumab)

Recruiting
  • Primary Central Nervous System Lymphoma
  • orelabrutinib
  • +2 more
  • Beijing, Beijing, China
    Wei Zhang
May 19, 2021

B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in China (Orelabrutinib, Recombinant humanized mAb MIL62 injection)

Recruiting
  • B-cell Lymphoma Recurrent
  • B-cell Lymphoma Refractory
  • Orelabrutinib
  • Recombinant humanized monoclonal antibody MIL62 injection
  • Bengbu, Anhui, China
  • +9 more
Aug 2, 2021

Diffuse Large B Cell Lymphoma Trial (Rituximab, Cyclophosphamide, Doxorubicin)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • (no location specified)
Apr 24, 2022

Relapsing Remitting Multiple Sclerosis Trial in Worldwide (, orelabrutinib)

Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • placebo
  • orelabrutinib
  • Ormond Beach, Florida
  • +41 more
Jan 28, 2022